Metoclopramide use during early pregnancy was not associated with excess risk for congenital malformations. In the U.S., treatment of nausea and vomiting during early pregnancy usually involves ...

Metoclopramide is used for the symptomatic treatment of post-operative or chemotherapy-induced nausea and vomiting, gastroesophageal reflux disease and gastroparesis. Metoclopramide is generally ...

Analysis of real-world data compared patients on GIMOTI (n=51) to Oral Metoclopramide (n=41), both taking GLP-1s, showing ...

Metoclopramide (as HCl) 5mg; mint flavor. Allow tablet to dissolve on tongue. 10–15mg 4 times daily 30mins before meals and at bedtime. Intermittent symptoms: up to 20mg prior to provoking ...

Metoclopramide stimulates motility of the upper gastrointestinal tract without stimulating gastric, biliary, or pancreatic secretions. The exact mechanism of action of metoclopramide in the ...

Evoke Pharma (EVOK) shares rocketed 90% on positive data for its nasal drug Gimoti in the treatment of stomach paralysis in ...

Evoke Pharma Inc (NASDAQ:EVOK) shares are trading higher Monday after the company presented GLP-1 data for users with ...

Approved to treat diabetic gastroparesis, Gimoti is co-marketed with Eversana. Evoke underlined that nasal delivery provides ...

Find all the commercial and brand names of generic drug called Metoclopramide. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...

Evoke Pharma shares rose 70% on Monday after presenting data on Gimoti in GLP-1 users. Shares were trading around $9 in recent trading. The stock is down more than 28% on the year so far.

Despite the recent stock surge, Evoke Pharma’s year-to-date performance tells a different story. The stock is down a notable 57.44%, starkly contrasting with the S&P 500’s impressive 21.77% gain. This ...

Evoke Pharma Inc. (EVOK) and Eversana Life Science Services, LLC. announced statistically significant comparative data on its study ...